OCT 06, 2020 8:30 AM PDT

New Immunotherapy Drug Effective Against Lung Cancer

WRITTEN BY: Annie Lennon

A new study has confirmed that Tecentriq, an immunotherapy drug, improves survival rates among those with newly diagnosed non-small cell lung cancers (NSCLC), which make up 85% of lung tumors. The drug was approved by the FDA earlier this year. 

Tecentriq (atezolizumab) is a checkpoint inhibitor drug. As such, it works by targeting a protein called PD-L1 that lies on the surface of tumor cells and signals the body’s immune system T cells not to attack certain pathogens. Targeting PD-L1 thus ensures that the body’s natural T cells do not get inhibited and can attack and destroy unwanted pathogens- in this case, cancer cells. 

For the study, researchers included 554 patients with stage 4 metastatic NSCLC tumors. All patients had tumors that lacked mutations in the EGFR and ALK genes, as patients with these markers tend to be better treated by other drugs. 

In the end, the researchers found that the 205 patients whose tumors had a high cellular expression of PD-L1, and who received Tecentriq, had a median overall survival rate of 20 months. Meanwhile, those who received the standard platinum-based chemotherapy treatment had an overall survival rate of just 13 months. 

The researchers also noted that median progression-free survival- the time taken from treatment to the disease worsening- was eight months for those on Tecentriq and five months for those on standard chemotherapy. 

Although generally well-tolerated among patients, the researchers say that they did not test the drug against an increasingly used treatment- standard chemotherapy in addition to immunotherapy drug, Keytruda. This, they say, is because the study started before these new treatments made it to clinical practice. As such, they say that usage of Tecentriq may nevertheless provide another non-chemotherapy treatment option for those with PD-L1-high lung cancer. 

 

Sources: WebMDNews Medical

About the Author
  • Science writer with a keen interest in behavioral biology, consciousness medicine and technology. Her current focus is how the interplay of these fields can create meaningful interactions, products and environments.
You May Also Like
JAN 18, 2021
Immunology
Arthritis Drug Approved for Critically Ill COVID Patients
JAN 18, 2021
Arthritis Drug Approved for Critically Ill COVID Patients
Critically ill COVID patients in the U.K. may receive an arthritis drug after a study showed that treatment lowered mort ...
JAN 21, 2021
Health & Medicine
Injectable Cannabis Overdose Drug Being Developed
JAN 21, 2021
Injectable Cannabis Overdose Drug Being Developed
It’s estimated that the number of visits to emergency rooms because of cannabis overdose tripled between 2011 and ...
JAN 20, 2021
Drug Discovery & Development
Designer Cytokine: Potential Therapeutic Approach for Paralysis
JAN 20, 2021
Designer Cytokine: Potential Therapeutic Approach for Paralysis
Paralysis due to spinal cord damage remains an irreparable condition. However, a new therapeutic approach may bring rene ...
JAN 26, 2021
Drug Discovery & Development
Gut Microbiota Reveals Drug Activity
JAN 26, 2021
Gut Microbiota Reveals Drug Activity
Inflammatory bowel diseases cannot be entirely cured but instead, the symptoms are treated with anti-inflammat ...
FEB 07, 2021
Drug Discovery & Development
Beta-Blockers Can Repair Broken Blood Vessels
FEB 07, 2021
Beta-Blockers Can Repair Broken Blood Vessels
Propranolol is a drug that can treat infantile haemangiomas but was found to also treat a blood vessel condition that le ...
MAR 15, 2021
Cell & Molecular Biology
When Sample Temperature Matters: How to Keep Your Cool in the Lab
MAR 15, 2021
When Sample Temperature Matters: How to Keep Your Cool in the Lab
Temperature control is critical to many molecular and cellular experiments, but managing sample temperature requires eit ...
Loading Comments...